Erik Orava, PhD (he/him/his)

Medical Advisor
Sanofi
Toronto, Ontario, Canada

Presentation(s):

• Dupilumab Reduced Exacerbations and Improved Lung Function and Asthma Control in Children With Uncontrolled, Moderate-to-Severe Asthma and Baseline High/Medium ICS Dose

  Saturday, May 4, 2024
  8:00 AM – 8:15 AM ET

  Disclosure(s): Sanofi (Ongoing) (Products/Services: Employment with an ineligible company, Ownership Interest including individual stocks, stock options, excluding diversified mutual funds)

• Improved Lung Function is Associated With Better Asthma Control in Children Aged 6 to 11 Years With Moderate-To-Severe Type 2 Asthma: A Post Hoc Analysis of VOYAGE

  Saturday, May 4, 2024
  8:15 AM – 8:30 AM ET

  Disclosure(s): Sanofi (Ongoing) (Products/Services: Employment with an ineligible company, Ownership Interest including individual stocks, stock options, excluding diversified mutual funds)